Journal of Antibiotics 2009-01-01

Modification of the antibiotic olivomycin I at the 2'-keto group of the side chain. Novel derivatives, antitumor and topoisomerase I-poisoning activity.

Anna N Tevyashova, Eugenia N Olsufyeva, Eugenia N Zbarsky, Jan Balzarini, Alexander A Shtil, Lyubov G Dezhenkova, Vladimir M Bukhman, Victor B Zbarsky, Maria N Preobrazhenskaya

Index: J. Antibiot. 62(1) , 37-41, (2009)

Full Text: HTML

Abstract

A novel way of chemical modification of the antibiotic olivomycin I at the 2'-keto group of the side chain of the aglycone moiety was developed. Reaction of olivomycin I with the carboxymethoxylamine hemihydrochloride gave the key intermediate, 2'-carboxymethoxime-olivomycin I, which was further reacted with different amines in the presence of benzotriazol-1-yl-oxy-trispyrrolidinophosphonium hexafluorophosphate to give the corresponding amides. The antiproliferative and topoisomerase I (Topo-I)-poisoning activities of the novel derivatives were examined. One of the novel derivatives showed a marked inhibitory activity against Topo-I, a pronounced antitumor activity in in vivo experiments on mice bearing leukemia P-388 and lower toxic side effects compared with the parent olivomycin I.


Related Compounds

  • 2-adamantaneamine...

Related Articles:

Simultaneous liquid chromatographic assay of amantadine and its four related compounds in phosphate-buffered saline using 4-fluoro-7-nitro-2,1,3-benzoxadiazole as a fluorescent derivatization reagent.

2006-05-01

[Biomed. Chromatogr. 20(5) , 423-8, (2006)]

[A quantitative pharmaco-electroencephalographic analysis of the action of bromantane].

1993-11-01

[Biull. Eksp. Biol. Med. 116(11) , 515-8, (1993)]

[DNA macroarray analysis of gene expression changes in rat brain after single administration of 2-aminoadamantane compound].

2005-01-01

[Mol. Biol. (Mosk.) 39(2) , 276-85, (2005)]

Inhibition of lymphocyte proliferation by amantadine and its isomer, 2-aminoadamantane; impact on Lyt-2+ T cells while sparing L3T4+ T cells.

1991-01-01

[Immunopharmacology 21(1) , 41-50, (1991)]

More Articles...